- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02731885
Food Effect on Pharmacokinetic Parameters of ABX464
An Open, Randomized Study, to Investigate the Potential Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a phase I, single-center, open-label, two-treatment, food-effect, randomized study in 40 healthy Caucasian male subjects in order to determine the impact of the food on the absorption of the ABX464.
The two different treatments are the followings:
- Treatment A = 50mg of ABX464 (two 25mg capsules) /Fasted
- Treatment B = 50mg of ABX464 (two 25mg capsules) / Fed
This study consists of two groups:
- Group 1 - single dose assessments, two-period, two-treatment, cross-over: 20 subjects will receive a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
- Group 2 - multiple dose assessments: 20 subjects will receive 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Phoenix
-
Sayed Hossen road, Phoenix, Mauritius
- CAP Research
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Healthy Caucasian male subjects, 18-55 years of age
- Body Mass Index (BMI) of 17-28 kg/m².
- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination)
Normal vital signs after 10 minutes resting in supine position:
90 mmHg < systolic blood pressure < 140 mmHg, 50 mmHg < diastolic blood pressure < 90 mmHg, 40 bpm < heart rate < 100 bpm.
- Normal automatic 12-lead ECG (incomplete right bundle branch block can be accepted) or judged as non clinically significant.
- Clinical laboratory tests (hematology, blood chemistry, and urinalysis) must be within normal limits or clinically acceptable to Investigator and Sponsor.
- Subjects must be willing to give written informed consent prior to study enrollment and be able to adhere to restrictions and examination schedules.
Exclusion Criteria:
- Individuals with a history of any significant medical disorder which requires a physician's care (cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic, or infectious disease; any acute infectious disease or signs of acute illness)
- Frequent headaches and / or migraine, recurrent nausea and / or vomiting (more than twice a month).
- Presence or history of drug allergy, or allergic disease diagnosed and treated by a physician.
- Individuals who have a history of any clinically significant local or systemic infectious disease within 4 weeks prior to drug administration.
- Any individual who does not comply with the requirement that he should not have used any drugs other than paracetamol for at least 2 weeks prior to the study nor alcohol within 48 hours prior to drug administration.
- Individuals who are positive for hepatitis B virus, hepatitis C virus or HIV.
- History or presence of drug or alcohol abuse (positive urine drug screen, positive alcohol breath test).
- Smoking more than 5 cigarettes or equivalent / day, unable to stop smoking during the study.
- Excessive consumption of beverages with xanthine bases (> 4 cups or glasses / day).
- Subject who will likely be unable to eat entirely the standard high fat breakfast within the allocated time.
- Individuals who have donated blood within the preceding 3 months.
- Individuals who refuse to use an effective method of contraception from the beginning of the study and until 3 months after dosing.
- Individuals with forfeiture of freedom by an administrative or legal obligation or under guardianship
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Fasted Conditions
50mg of ABX464 (two 25mg capsules) /Fasted
|
Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
|
|
Eksperimentel: Fed Conditions
50mg of ABX464 (two 25mg capsules) /Fed
|
Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Area under the plasma concentration versus time curve (AUC) of single oral dose of 50mg of ABX464 in fed or fasted condition.
Tidsramme: 45 days
|
45 days
|
|
Peak Plasma Concentration (Cmax) of single oral dose of 50mg of ABX464 in fed or fasted condition.
Tidsramme: 45 days
|
45 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Area under the plasma concentration versus time curve (AUC) of repeated doses of 50 mg of ABX464 in fed or fasted conditions
Tidsramme: 10 days
|
10 days
|
|
Peak Plasma Concentration (Cmax) of repeated doses of 50 mg of ABX464 in fed or fasted conditions
Tidsramme: 10 days
|
10 days
|
|
Number of Subjects with treatment-related adverse events as assessed by CTCAE v4.0
Tidsramme: Up to 45 days
|
Up to 45 days
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- ABX464-FE-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med ABX464 Single dose
-
Tongji HospitalRekrutteringRemimazolam | Vågen endotracheal intubationKina
-
Abivax S.A.AfsluttetHIV-infektioner | SundhedsfrivilligeSpanien
-
Abivax S.A.AfsluttetRheumatoid arthritisBelgien, Frankrig, Ungarn, Polen
-
Abivax S.A.AfsluttetCOVID-19Spanien, Det Forenede Kongerige, Tyskland, Belgien, Frankrig, Italien, Brasilien, Mexico
-
Abivax S.A.AfsluttetColitis ulcerosaForenede Stater, Israel, Det Forenede Kongerige, Spanien, Irland, New Zealand, Italien, Kroatien, Polen, Bulgarien, Tyskland, Ungarn, Serbien, Belgien, Tjekkiet, Japan, Canada, Rumænien, Indien, Brasilien, Slovakiet, Mexico, Litauen, F... og mere
-
Abivax S.A.AfsluttetColitis ulcerosaSpanien, Forenede Stater, Kina, Belgien, Australien, Østrig, Italien, Indien, Portugal, Bulgarien, Ungarn, Holland, Polen, Tyskland, Canada, Grækenland, Frankrig, Tjekkiet, Det Forenede Kongerige, Schweiz, Argentina, Ukraine, Tyrkiet... og mere
-
Abivax S.A.Aktiv, ikke rekrutterendeColitis ulcerosaBelgien, Ungarn, Østrig, Spanien, Frankrig, Polen, Tyskland, Canada, Tjekkiet, Italien, Slovakiet, Slovenien, Serbien, Ukraine
-
Abivax S.A.Orion Corporation, Orion PharmaAfsluttet
-
Abivax S.A.AfsluttetColitis ulcerosaPolen, Spanien, Frankrig, Tyskland, Italien, Slovenien, Belgien, Canada, Hviderusland, Ungarn, Østrig, Det Forenede Kongerige, Tjekkiet, Serbien, Slovakiet, Ukraine